June 30 (Reuters) - Amplia Therapeutics Ltd ATX.AX :
* RECEIVED PRELIMINARY FINAL RESULTS FROM PRECLINICAL TOXICOLOGY STUDIES BEING CONDUCTED WITH ITS FAK INHIBITOR, AMP945
* PRECLINICAL TOXICOLOGY STUDIES SUPPORT PLANNED PHASE 1 CLINICAL TRIAL
June 30 (Reuters) - Amplia Therapeutics Ltd ATX.AX :
* RECEIVED PRELIMINARY FINAL RESULTS FROM PRECLINICAL TOXICOLOGY STUDIES BEING CONDUCTED WITH ITS FAK INHIBITOR, AMP945
* PRECLINICAL TOXICOLOGY STUDIES SUPPORT PLANNED PHASE 1 CLINICAL TRIAL